Company integrates leading medical imaging technology with image management and reporting system provided by Digisonics.
Boston, MA-June 2, 2008-Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation, today announced that it has integrated its leading medical imaging technology with the functionality of DigiView, a specialized image management and reporting system provided by Digisonics, to offer clients expanded capabilities for cardiac function assessment in clinical studies. The system provides high-performance electronic review, analysis, reporting, and archiving of medical images related to cardiac function assessment. Cardiac function assessment is required for a broad range of therapeutic area research, including cardiology, oncology, central nervous system, and metabolism/endocrinology studies.
As cardiac safety has become a greater regulatory focus for various compounds, biopharmaceutical companies increasingly turn to us for cardiac evaluations to support the demonstration of safety and efficacy," said Todd A. Joron, corporate vice president and general manager of Perceptive Informatics at PAREXEL International. "By combining this tool with our leading medical imaging technology and in-depth expertise, we are able to help clients better meet their cardiovascular imaging needs."
The integrated Perceptive and DigiView system, which supports various cardiovascular imaging modalities, provides several capabilities, including faster, more accurate review of cardiac images as well as automatic synchronization of image analysis findings with other clinical data through an electronic Case Report Form. The system provides an electronic record of all image analysis versions and exceeds HIPAA requirements for providing security and a regulatory audit trail, as well as capturing electronic signatures. Perceptive Informatics' medical imaging technology is fully validated and in compliance with regulatory guidelines.
The Perceptive Informatics Medical Imaging division leverages advanced technology to help ensure the effective use of imaging surrogate endpoint data as well as secure data access and back-up. The Perceptive Informatics medical imaging team operates globally and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and metabolism/endocrinology.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.